Two of President Trump’s top health nominees are on a collision course as the incoming administration faces a crucial decision on coverage for groundbreaking anti-obesity drugs. Mehmet Oz, President-elect Trump’s pick to run the Centers for Medicare and Medicaid Services, has extolled the benefits of anti-obesity drugs like Ozempic, pitching them on his show and…
Source link
